Market Access Views from Asembia: EVERSANA's take on outsourcing, AI, and ... Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.
News November date set for FDA decision on Sanofi's Gaucher drug The FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
